Relapsed or Refractory Diffuse Large B Cell Lympho

A Global Strategic Business Report

MCP34285

RESEARCH DASHBOARD

OCT 2025

RELEASE DATE

7152

EXECUTIVE POOL

5850

PRICE

818

EXPERT INPUTS

48

COMPANIES

216

DATA TABLES

294

PAGES

2

EDITION

WHAT'S BEHIND OUR DATA?

140857226

DOMAIN TRANSCRIPTS

6080276

BRANDS TRACKED

1729341

FEATURED COMPANIES

22574

TOPICS COVERED

82719

MARKET SEGMENTS

91

KEY INDUSTRIES

1574

CURATION TEAM

4761909

DECISION MAKERS

EXECUTIVE ENGAGEMENTS BY TIER (55)

3

CXO

5

VICE PRESIDENT

10

DIRECTOR

25

MANAGER

12

MARKETING

REQUEST FULL-STACK INDEX Includes 350+ pages validated sources

QUESTIONNAIRE EXECUTIVES DATA ROOM

OUR EXPERT PANELS

Panelists are carefully chosen based on their domain expertise and market influence.

Participation in our expert panels is only by invitation. Our project focused panels are constituted of senior executives in business strategy, marketing, sales, and product management at competitive companies worldwide. We also welcome individuals from leading management consulting, venture capital, private equity, investment management and related firms with domain expertise and are actively monitoring specific companies or industries. Our panelists bring unique market perspectives and unbiased intelligence to our ongoing research programs.

INFLUENCER INVITEE

WHY PARTICIPATE?

Expertise to the Power of YOU!

Collaborative Insights - Expand your deep domain insights from participants at competitive companies worldwide while you share your own!
Global Acumen Alerts - Expand your intelligence on your areas of interest by enabling our “Email Alerts” feature drawing from other influencers’ project participation.
Enterprise-wide Project Discounts - Discounts start @ 10% and build up as more participants support our ongoing projects in your space.
Complimentary Copies - We highly recommend collaboration with your team to draw upon their geographical domain expertise. Our platform enables collaborative engagements with 10 peers. When you or any of your team members purchase the report, the entire team will receive complimentary copies with full stack access to our data and updates for one year.
Annual Digital Subscription to one of the business publications or $100 value gift card - No Purchase Required! The lead participant will receive the digital subscription

The Economist
MIT Technology Review
Harvard Business Review

Note - Offer is limited to one participant per company. Offer may be withdrawn at anytime without notice once our annual maximum participation of leading players is fulfilled. Offer by invitation only, to enterprise executives in from companies featured in the project ranked. If you’ve received our initation, you’re qualified! If not, you may check your eligibility by registering to join our Project Expert Panel. Typically you must be have a Marketing, Strategy, Product Management or Business Development, role as a CXO or VP or Director or Manager directly involved with the P&L of the products or services covered in the report. You must complete all modules in the Primary Research Data Simulator.

MARKETGLASS

BASIC

Annual Prepaid Subscription
Single-User
10,000 Data Room Credits/Month
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use MarketGlass^TM Data Templates For Your Own Enterprise Data to Build Bespoke Research Reports.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.

PREMIUM

Annual Prepaid Subscription
One Research Project With One Complimentary Update/Year
10-User License
10-User Peer-to-Peer Collaborative Features
200 Domain Expert Insights (With Name, Company, and Date)
50,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

ENTERPRISE

Annual Prepaid Subscription
Four Research Projects With One Complimentary Update/Year
25-User License
25-User Peer-to-Peer Collaborative Engagements
500 Domain Expert Insights (With Name, Company, and Date)
150,000 Data Room Credits
Research Tool - Unlimited Access to Build Your Own Search Engine Data & Domain Expert Video Transcriptions.
Use Publisher's Market Data Templates to Simulate & Build Your Bespoke Variations to Published Data (4 Reports/Year)
Use Your Own Data and MarketGlass^TM Data Room Content.
My Silo - Build Your Private Data Room for Generative AI and Other Applications. Download Data Stacks For External Applications & Language Models.
Add Extra Topics/Reports During The Year At Regular Prices With Full Platform Privileges

HIGHLIGHTS & REPORT INDEX

Global Relapsed or Refractory Diffuse Large B Cell Lympho Market to Reach US$1.8 Billion by 2030

The global market for Relapsed or Refractory Diffuse Large B Cell Lympho estimated at US$1.5 Billion in the year 2024, is expected to reach US$1.8 Billion by 2030, growing at a CAGR of 2.9% over the analysis period 2024-2030. Monjuvi, one of the segments analyzed in the report, is expected to record a 1.7% CAGR and reach US$456.4 Million by the end of the analysis period. Growth in the XPOVIO segment is estimated at 3.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$408.0 Million While China is Forecast to Grow at 5.3% CAGR

The Relapsed or Refractory Diffuse Large B Cell Lympho market in the U.S. is estimated at US$408.0 Million in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$343.0 Million by the year 2030 trailing a CAGR of 5.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 1.2% and 2.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.6% CAGR.

Global “Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)” Market – Key Trends & Drivers Summarized

Why Is Relapsed or Refractory DLBCL a Persistent Challenge in Oncology?
Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, accounting for approximately 30% of all NHL cases worldwide. While first-line therapies such as R-CHOP (rituximab with chemotherapy) achieve remission in a significant number of patients, about 30–40% experience relapse or do not respond to initial treatment—classified as relapsed or refractory (R/R) DLBCL. This patient subgroup faces a poor prognosis, with limited curative options. The heterogeneity of the disease, often driven by genetic abnormalities like MYC, BCL2, and BCL6 rearrangements, complicates treatment strategies. Conventional salvage therapies such as high-dose chemotherapy followed by autologous stem cell transplant are often unsuitable due to age or comorbidities, leaving a therapeutic gap. The unmet clinical need in this space is immense, spurring ongoing research and innovation in both targeted and cellular immunotherapies.

How Are Innovative Therapies Transforming the Outlook for R/R DLBCL Patients?
Breakthrough therapies are redefining the standard of care for R/R DLBCL and bringing renewed hope to patients who were previously considered incurable. Among the most impactful innovations are chimeric antigen receptor T-cell (CAR-T) therapies, including axicabtagene ciloleucel and tisagenlecleucel, which have shown substantial complete remission rates even in heavily pre-treated patients. These personalized cell-based therapies reprogram a patient`s own immune cells to recognize and kill lymphoma cells. In parallel, antibody-drug conjugates (ADCs) like polatuzumab vedotin and bispecific antibodies such as glofitamab are emerging as viable off-the-shelf options with high efficacy and manageable toxicity profiles. Small molecule inhibitors targeting key pathways such as BTK, PI3K, and BCL2 are also under active investigation. The development of these therapies reflects a broader trend toward precision oncology, where treatments are increasingly tailored to the molecular profile of the patient’s disease, transforming once-fatal relapses into manageable chronic conditions or potential cures.

Which Healthcare and Market Dynamics Are Shaping the Adoption of These Therapies?
The R/R DLBCL treatment market is being shaped by a convergence of regulatory, healthcare system, and payer dynamics. Regulatory bodies such as the FDA and EMA have granted accelerated approvals and breakthrough designations to several advanced therapies, fast-tracking access and incentivizing further R&D. However, high treatment costs, especially for CAR-T therapies, have sparked debate over reimbursement models and accessibility. Payers are increasingly evaluating outcomes-based contracts and value-based care agreements to manage the financial risk of adopting these high-cost therapies. Healthcare providers are also investing in infrastructure and training for administering complex treatments like CAR-T, which require specialized centers and multidisciplinary teams. Meanwhile, pharmaceutical companies are developing next-generation CAR-Ts with reduced manufacturing times and off-the-shelf formats to improve scalability and reduce treatment delays. Patient advocacy groups and digital platforms are also playing a role by increasing awareness, supporting access programs, and connecting patients to clinical trials.

The Growth in the Relapsed or Refractory DLBCL Market Is Driven by Breakthrough Immunotherapies, Precision Oncology Trends, and Infrastructure Expansion for Complex Biologics
The growth in the relapsed or refractory DLBCL market is driven by several interlinked factors. Chief among them is the rise of next-generation immunotherapies—particularly CAR-T cell therapies, ADCs, and bispecific antibodies—which are transforming survival outcomes for patients with limited options. Secondly, the adoption of precision medicine, enabled by genomic profiling and companion diagnostics, is allowing oncologists to identify high-risk DLBCL subsets and match them with targeted therapies. Thirdly, improvements in biopharmaceutical manufacturing, including automation and decentralized CAR-T production models, are enhancing the accessibility and scalability of advanced treatments. Fourthly, growing investments by hospitals and oncology centers in cell therapy units and specialized infusion facilities are making it easier to deliver complex biologics safely and efficiently. Additionally, supportive healthcare policies, fast-track approvals, and expanded clinical trial networks are helping bring innovative therapies to market faster. Lastly, patient demand for more durable and less toxic alternatives to traditional chemotherapy is pushing physicians and payers to adopt these novel therapies as part of an evolving standard of care.

SCOPE OF STUDY

The report analyzes the Relapsed or Refractory Diffuse Large B Cell Lympho market by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Type (Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta, Other Drug Types); Distribution Channel (Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies).

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa..

SELECT PLAYERS

AbbVie Inc.; Adaptive Biotechnologies Corp.; ADC Therapeutics SA; Bristol Myers Squibb; Cellular Biomedicine Group Inc.; Eagle Pharmaceuticals, Inc.; Genmab A/S; Gilead Sciences, Inc.; Hoffmann-La Roche AG; IMV Inc.; Incyte Corporation; Janssen Biotech, Inc.; Karyopharm Therapeutics; Merck & Co., Inc.; MorphoSys U.S. Inc.; Novartis AG; Overland Pharmaceuticals; Pfizer Inc.; Regeneron Pharmaceuticals; Takeda Pharmaceutical Company

AI INTEGRATIONS

We’re transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

I. METHODOLOGY

II. EXECUTIVE SUMMARY

1. MARKET OVERVIEW

Trade Shocks, Uncertainty, and the Structural Rewiring of the Global Economy

World Market Trajectories

How Trump’s Tariffs Impact the Market? The Big Question on Everyone’s Mind

Relapsed or Refractory Diffuse Large B Cell Lympho – Global Key Competitors Percentage Market Share in 2025 (E)

Competitive Market Presence - Strong/Active/Niche/Trivial for 48 Players Worldwide in 2025 (E)

2. FOCUS ON SELECT PLAYERS

3. MARKET TRENDS & DRIVERS

Rising Incidence of Non-Hodgkin Lymphoma Drives Demand for Second-Line Treatment Options

Breakthrough Approvals in CAR-T Cell Therapy Expand Advanced Treatment Availability

Pipeline Development of Bispecific Antibodies Spurs Competitive Innovation

Shift Toward Personalized Oncology Enhances Role of Genomic Profiling in R/R DLBCL Treatment

Increased Clinical Trial Activity Across Immunotherapy Classes Expands Market Opportunities

Regulatory Fast Track Designations Accelerate Access to Novel Drug Classes

Adoption of Antibody-Drug Conjugates (ADCs) Strengthens Outcomes in Refractory Patients

Growing Hospital Investment in Cell Therapy Infrastructure Supports CAR-T Commercialization

Rise in Patient Assistance Programs Enhances Access to High-Cost Treatment Modalities

Use of Companion Diagnostics Improves Patient Stratification and Therapeutic Precision

Strategic Pharma Collaborations Fuel Co-Development of Targeted Agents

Expansion of Academic Research into Resistance Mechanisms Spurs Innovation

Shift from Chemotherapy-Dependent Approaches to Immuno-Oncology Alters Treatment Landscape

Global Expansion of Cell Therapy Manufacturing Capacity Increases Access in Emerging Markets

Increasing Physician Familiarity with Multi-Line Treatment Protocols Improves Uptake

4. GLOBAL MARKET PERSPECTIVE

World Relapsed or Refractory Diffuse Large B Cell Lympho Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030

World Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Monjuvi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Monjuvi by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Monjuvi by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for XPOVIO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for XPOVIO by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for XPOVIO by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Polivy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Polivy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Polivy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Kymriah by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Kymriah by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Kymriah by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Yescarta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Yescarta by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Yescarta by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Other Drug Types by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Other Drug Types by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Hospitals Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Hospitals Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Retail Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Retail Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

World Recent Past, Current & Future Analysis for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

World Historic Review for Online Pharmacies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

World 15-Year Perspective for Online Pharmacies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

UNITED STATES

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)

USA Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

USA Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

USA Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

USA 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

CANADA

Canada Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Canada Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Canada Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Canada 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

JAPAN

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)

Japan Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Japan Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Japan Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Japan 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

CHINA

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)

China Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

China Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

China Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

China 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

EUROPE

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)

Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

FRANCE

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)

France Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

France Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

France Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

France 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

GERMANY

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)

Germany Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Germany Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Germany Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Germany 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

ITALY

Italy Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Italy Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Italy Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Italy 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

UNITED KINGDOM

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)

UK Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

UK Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UK Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

UK 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

SPAIN

Spain Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Spain Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Spain Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Spain 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

RUSSIA

Russia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Russia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Russia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Russia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

REST OF EUROPE

Rest of Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Rest of Europe Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Europe Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Europe 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

ASIA-PACIFIC

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)

Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

AUSTRALIA

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)

Australia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Australia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Australia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Australia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

INDIA

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)

India Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

India Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

India Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

India Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

India 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

SOUTH KOREA

South Korea Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

South Korea Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

South Korea Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

South Korea 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

REST OF ASIA-PACIFIC

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Rest of Asia-Pacific Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Asia-Pacific Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Asia-Pacific 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

LATIN AMERICA

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)

Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

ARGENTINA

Argentina Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Argentina Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Argentina Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Argentina 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

BRAZIL

Brazil Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Brazil Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Brazil Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Brazil 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

MEXICO

Mexico Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Mexico Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Mexico Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Mexico 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

REST OF LATIN AMERICA

Rest of Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Rest of Latin America Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Latin America Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Latin America 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

MIDDLE EAST

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)

Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR

Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

IRAN

Iran Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Iran Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Iran Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Iran 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

ISRAEL

Israel Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Israel Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Israel Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Israel 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

SAUDI ARABIA

Saudi Arabia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Saudi Arabia Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Saudi Arabia Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Saudi Arabia 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

UNITED ARAB EMIRATES

UAE Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

UAE Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

UAE Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

UAE 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

REST OF MIDDLE EAST

Rest of Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Rest of Middle East Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Rest of Middle East Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Rest of Middle East 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

AFRICA

Relapsed or Refractory Diffuse Large B Cell Lympho Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)

Africa Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Drug Type - Percentage Breakdown of Value Sales for Monjuvi, XPOVIO, Polivy, Kymriah, Yescarta and Other Drug Types for the Years 2015, 2025 & 2030

Africa Recent Past, Current & Future Analysis for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR

Africa Historic Review for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR

Africa 15-Year Perspective for Relapsed or Refractory Diffuse Large B Cell Lympho by Distribution Channel - Percentage Breakdown of Value Sales for Hospitals Pharmacies, Retail Pharmacies and Online Pharmacies for the Years 2015, 2025 & 2030

COMPETITIVE METRICS

COMPETITORS (ALPHABETICAL)	% VALIDATED RESEARCH *

* Login to Participate & View Data Stacks

* Participating executives must be from a competitive company. Executive credentials are validated by a one-time two-factor authentication, in compliance with GDPR guidelines. Verified executives have complimentary access to our proprietary MarketGlass^TM platform and relevant data silos including Trend Data; Brand/IP/TM Feeds; and Market Size, Share & Rank Clusters. Qualified influencers are also invited to join our Expert Panels. Privileges include purchase credits, and collaborative bespoke builds.

View All Companies...

PARTICIPATE NOW!

PREVIEW REPORT

YOUR PRIVACY MATTERS!

Our robust permission-based engagement strategy requires a one-time double opt-in and/or re-consent for all users. We will re-establish consent once a year from date of last use. Both these practices exceed GDPR mandates.

What we store: Primary coordinates such as email, company address and phone. In-house developed influencer rank.
How we store: Encrypted and additionally secured by firewalls.
How we use your data: Only to contact you directly. We never share your coordinates with any individual or entity outside our company for any reason.
Privacy queries: [email protected]

DIFFERENTIATORS

Integrity Trust Transparency

Our research offerings primarily draw upon unique perspectives of participating executives and their experiences in operating and strategy roles. These geo-focused insights enrich our projects .

What we are NOT - Our reports are not editorial exercises of remote analysts’ secondary source fed content that predominantly flood today’s off-the-shelf market report business. (A review of 262 publishers).

WHAT SETS US APART

FULL STACK DATA ACCESS

Primary Research Cluster Data
Influencer Engagement Stats
Evidence of Primary Research
List of Companies Engaged
Hundreds of Pages of Research
Peer Collaborative Interactions
Enterprise Data Exchanges
MarketGlassTM Platform Insider
Geographic Pricing Dynamics
Competitive Shares by Country
Brand Curation & Insights
Domain Expert Pool

Program Transparency: Clients have access to engagement stats of companies and executives. Clients may commission third-party audits of our influencer engagements at their expense.

Primary Research: We have a very successful incentive driven primary research program presenting a rich experience to participating executives. Featured company executives can sign up for a complimentary.

Collaborative Intelligence: Our platform presents a unique features for executives to collaborate with peers across geographies and participate on various product or regional perspectives for a collective unified insider project experience.

Global Brand Intelligence: We present competitive brand intelligence at the company level for players worldwide. Executives from brand owner companies participate to curate each brand for relevance and market presence.

Bespoke Updates: Our peer-to-peer online interactive platform enables client companies to build upon our project data stacks to build bespoke editions for internal sharing and use. Client company can build one complimentary update per year and unlimited updates for additional fee. Bespoke updates are fulfilled within a two-day turnaround.

Enterprise EcoConnect: Discretely bounce off queries to participant pool of executives. We can reach out to our participant pool based on specifics of geographic or domain acumen.

Renowned Support: We pride in our commitment to provide support to our clients. We go beyond the scope of the study to get you timely answers.

Complimentary Updates: Unlike the industry’s published PDF’s that are frozen in time from date of release, our research programs are ongoing and dynamic. Our reports are updated whenever there’s a major event impacting the marketplace. Your license offers seamless updates for one year.

No Fluff: We offer our clients the best CX with clean easy to read content. No verbose fluff. We offer clients full access to the entire stack of hundreds of pages of secondary research feeds used in our project via our online MarketGlass portal.

Scroll